Osteonecrosis of the jaws in patients treated with bisphosphonates.

Introduction

Bisphosphonate-induced osteonecrosis of the jaws (ONJ) was first described by Marx in the year 2003 ( 1 ). The disease is characterized by the exposure for over 8 weeks of necrotic bone in the maxillofacial region, after bisphosphonate (BP) therapy, in the absence of prior maxillary radiotherapy ( 2 - 4 ). Although the condition is typically confined to the maxillofacial region, there have been reports of cases in the hip, tibia and femur ( 5 ). The reason for such exclusive involvement of the jaws is subject to controversy. In this sense, many factors could be implicated, including the anatomical characteristics of alveolar bone, its fine overlying epithelial layer, mechanical stress caused by chewing, inflammatory processes (periodontitis), and a complex oral microbiota involving the presence of bacteria such as Fusobacterium, Bacillus, Actinomyces, Staphylococcus, Streptococcus, Selenomonas and Treponema ( 6 , 7 ). Oral bisphosphonates are indicated for the treatment of osteopenia, osteoporosis and Paget’s disease ( 4 ), while intravenous bisphosphonates are used in patients with cancer and bone metastases, for the prevention of bone complications (pathological fractures, spinal cord compression and problems related to bone irradiation and/or surgery), and for the treatment of tumor-induced hypercalcemia ( 4 , 8 ). The appearance of osteonecrosis is a serious complication that affects patient quality of life and causes important morbidity ( 2 , 9 ).

The incidence of ONJ is estimated to be 0.01-0.04% in the case of oral BP treatment, versus 0.7-12% in the case of intravenous BP administration ( 4 , 9 ) – this percentage reaching 21% when these drugs are administered for three or more years ( 10 ). In addition to the administration route employed, these differences are due to other factors such as the treatment indication, potency, administered dose and the duration of treatment ( 11 ).

The present study reviews the literature on the etiopathogenesis, risk factors, clinical forms, diagnosis, treatment and prevention of bisphosphonate-induced osteonecrosis of the jaws.

Material and Methods

A PubMed-Medline search was carried out with the following key words: “bisphosphonates” and “osteonecrosis”. A total of 382 articles published in the last two years were reviewed. Of these, we excluded 31 studies in languages other than English and 30 studies in animals. Apart from these 321 initially considered articles, we also included other publications derived from manual searches and from references in review articles that were regarded as important. Study selection was based on a review of the titles and abstracts, with a view to obtaining the full texts of those publications considered to be of relevance in terms of the quality of their methodological design. The articles obtained from the search were classified as corresponding to the following areas: etiopathogenesis, risk factors, clinical forms and histology, diagnosis and treatment, and prevention. In addition, Table 1 includes all the series involving over 15 patients diagnosed with bisphosphonate-induced ONJ between 1 January 2011 and 15 May 2011.

Table 1 Bisphosphonate-induced osteonecrosis of the jaws in published series involving more than 15 patients.

Etiopathogenesis

The molecular structure of the bisphosphonates is similar to that of the pyrophosphates, with the exception that the former have a P-C-P bond at the center of the structure ( 3 ). Bisphosphonates inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase. Once bound to bone, they prevent bone resorption mediated by osteoclasts, and stimulate apoptosis of these cells. Bisphosphonates have also been reported to exert an antiangiogenic effect through the suppression of serum interleukin levels generated by the endothelial cells ( 3 , 17 ). A number of factors have been related to the etiopathogenesis of ONJ, such as immune disorders and alterations of the reparatory mechanisms, since 95% of all patients with ONJ present tumors as background disease. Although vascular impairment has been postulated as one of the key elements in the etiopathogenesis of ONJ, the latter has also been erroneously linked to avascular necrosis in other locations such as the hip, since there are no clinical or physiopathological parallelisms between the two disorders. Diminished bone turnover and toxicity at both bone level and in the soft tissues have also been cited as etiopathogenic factors ( 18 ). Bisphosphonates have been reported to act directly upon keratinocytes and fibroblasts, inhibiting their activities through aging processes and apoptosis. This in turn affects cell proliferation and migration, resulting in a lack of reepithelization of the oral mucosa ( 19 ). Although the physiopathology of ONJ remains to be fully clarified, the inhibition of bone remodeling has been suggested to play a significant role. The best evidence in support of this hypothesis comes from patients not treated with bisphosphonates. There have been reports of ONJ in patients treated with drugs such as denosumab that inhibit bone remodeling by acting upon the RANKL receptor ( 20 ). There have also been descriptions of ONJ without previous BP treatment in patients with herpes-zoster infections and HIV-positive individuals ( 21 ).

The half-life of the bisphosphonates in blood is short (between 30 minutes and 2 hours), though once bound to bone these drugs can persist within the body for years ( 1 ). Although the presence of bacteria has been demonstrated in patients with BP-induced ONJ, it is not clear whether infection is a primary or a secondary cause of the disorder ( 2 , 10 ).

Many patients present antecedents of local trauma, particularly dental extractions (70%), with a lesser incidence of other surgical procedures. ONJ has been reported to develop spontaneously in 30-50% of the cases ( 8 , 22 ), particularly in locations where the gingival mucosa is thinner ( 2 , 10 ).

In a review of 468 dental implants in 115 patients subjected to oral BP therapy, no cases of ONJ were observed, and only two implants failed. The success rate was therefore similar to that recorded in patients without BP treatment. In the absence of other diseases or medications, the placement of implants and their osteointegration during the first three years of treatment with oral bisphosphonates can be regarded as safe ( 23 ). In another retrospective study ( 24 ) involving implant placement in 61 patients treated with oral bisphosphonates for an average of 3.3 years, no cases of ONJ were recorded during follow-up (12-24 months), and the implant success rate was 100%. Nevertheless, it must be taken into account that a number of authors ( 7 , 9 , 11 , 22 , 25 ) have described cases of BP-induced ONJ in patients with dental implants.

Risk factors

A number of studies ( 2 - 4 , 14 , 26 ) have analyzed the risk factors underlying of BP-induced ONJ. Treatment with potent intravenous bisphosphonates such as zolendronate or pamidronate, and tooth extractions, are the most important factors, with an estimated risk of between 6.7% and 9.1% after extraction ( 4 ). Other potentially influencing factors are periodontal or periapical surgical procedures, the presence of dental abscesses, anatomical factors such as the presence of a torus, the duration of BP treatment, the number of treatment cycles, diabetes, deficient oral hygiene and the concomitant administration of corticosteroids or thalidomide ( 2 , 6 , 17 , 27 ). A genetic influence has also been postulated in the development of the disease through the cytochrome P450-2C enzyme system (CYP2C8), since the latter is implicated in the arachidonic acid metabolism and cholesterol biosynthesis, and can modulate angiogenesis and osteoblast differentiation in bone ( 3 , 10 ).

Clinical forms and histology

Table 2 describes the different potential clinical stages of BP-induced ONJ. Patients complain of progressive and persistent pain, following an initially asymptomatic period. The disorder often produces suppuration through gingival fistulas, with posterior exposure of necrotic maxillary or mandibular bone through the mucosa. Clinically, these exposed bone areas measure between 0.5-2 cm in diameter, and several simultaneous exposure sites are frequently observed in one same patient ( 28 ). In addition, other less common manifestations include loss of sensitivity in the territory innervated by the inferior alveolar nerve (Vincent’s sign) ( 10 ). Regarding the location of these areas, mandibular involvement is much more common than maxillary bone exposure, and in the mandible the molar region is particularly susceptible ( 22 ) – possibly due to the presence of terminal vascularization ( 6 ) that cannot be compensated by peripheral perfusion from the gingiva and periodontal tissue.

Table 2 Proposed staging classification and treatment of bisphosphonate-induced osteonecrosis of the jaws (32)..

The histological characteristics in turn comprise osteomyelitis with an inflammatory infiltrate of the necrotic tissue, while the adjacent zones show the presence of Actinomyces and pseudoepitheliomatous hyperplasia ( 15 ).

Diagnosis and treatment

A number of diagnostic criteria for osteonecrosis of the jaws have been proposed ( 8 ):

Patients receiving or who have received BP therapy.

The presence of one or more ulcerated lesions affecting the mucosa of the alveolar processes, with the exposure of maxillary or mandibular bone. There also may be cases without bone exposure, with pain or fistulas, that should be subjected to more detailed study.

Exposed bone of necrotic appearance.

Lesions manifesting spontaneously or, more often, after dental-alveolar surgery (particularly extractions).

Absence of healing over a period of at least 6 weeks.

Computed tomography (CT) is effective in assessing the size and extent of the necrotic bone, and magnetic resonance imaging (MRI) can also be used to evaluate osteonecrosis, showing diminished signal intensity in T1- and T2-weighted sequences. The appearance of ONJ on X-rays and in the CT scan is variable and includes poorly defined areas with a permeated appearance showing cortical destruction, bone sequestration, periosteal reaction or sclerotic changes. The presence of sclerosis associated to a disorganized microtrabecular structure could represent the first imaging signs of BP-induced ONJ. The presence of a periosteal reaction and bone sequestration in turn is associated to more advanced stage disease ( 29 ).

Ruggiero et al. ( 30 ) have proposed a clinical classification that can be used for staging ONJ and for planning treatment. This system includes two new stages with respect to the previous classification: the designation of “risk category” for those patients treated with oral or intravenous bisphosphonates who do not show exposure of necrotic bone; and “stage 0” referred to those patients who in the absence of clinical evidence of bone exposure show nonspecific clinical manifestations such as mandibular pain or osteosclerosis ( 31 ). A new modification proposed by Bagán et al. ( 32 ), which has been supported by other authors ( 33 ), is described in Table 3 . In this classification stage 2 is subdivided according to whether the patient remains stable without progression or worsening of necrosis or of the signs derived from necrosis (stage 2a), or whether the condition progresses in terms of the extent of necrosis or of its derived infectious complications, without producing mandibular fracture, extraoral fistula or osteolysis (stage 2b). However, in contrast to the classification proposed by Ruggiero et al. ( 30 ) and posteriorly modified by Bagán et al. ( 32 ), Woo et al. ( 33 ) advises subdividing stage 0 according to the patient symptoms. Thus, a distinction is made between stage 0sa (suspected asymptomatic), corresponding to patients without bone exposure but with fistulas or deep periodontal pockets causing no symptoms and treated only with chlorhexidine rinses; and stage 0ss (suspected symptomatic), corresponding to patients without bone exposure but with fistulas or deep periodontal pockets causing symptoms and treated only with chlorhexidine rinses and systemic antibiotics.

Table 3 General recommendations in patients receiving intravenous bisphosphonate treatment (8).

The treatment of these patients remains the subject of debate. The objective of treatment in patients diagnosed with ONJ should be to eliminate the pain, control the soft tissue and bone infection, and avoid or reduce the progression of bone necrosis. Several authors ( 22 , 30 ) consider that the suppression of oral BP treatment for a period of 6-12 months results in clinical improvement and even spontaneous resolution of the condition. Suspension is therefore advisable, provided the systemic clinical conditions of the patient allow the interruption of BP therapy. Since 25% of trabecular bone and 3% of cortical bone are renewed each year, the interruption of BP treatment theoretically could have a beneficial effect, since the newly formed bone is unable to absorb BP ( 14 ). However, in a study involving 25 patients, BP suppression was not seen to exert an effect ( 9 ). Corticosteroid discontinuation also should be considered in patients concomitantly receiving these drugs as maintenance therapy ( 34 ). It has been suggested that these patients should receive conservative management, since the mucosal disruptions resolve in at least 23-53% of the cases after following a series of recommendations: administration of topical chlorhexidine and systemic antibiotics in cases of pain and infection, the suppression of BP treatment, or hyperbaric oxygen therapy ( 17 , 25 ). A preliminary study ( 27 ) of 10 patients has described a conservative treatment option based on direct ozone (O3) application in gel form, thereby facilitating ozone release over the necrotic bone. Beneficial results were obtained, since in two patients (20%) the radiological controls showed disappearance of the lesions and complete regeneration of the oral tissues. The shedding of bone sequestration was recorded in 8 patients (80%), with complete reepithelization of the lesions in two cases. There were no cases of ONJ relapse after 8 months of follow-up. Such therapy therefore should be regarded as an effective, safe and simple treatment option in application to BP-induced ONJ measuring ≤ 2.5 cm in size. Another described treatment option is the administration of isoprenoid geranyl diphosphate (metabolic form of geraniol), which reverts inhibition of the mevalonate pathway induced by nitrogenated bisphosphonates ( 35 ).

Bocanegra-Pérez et al. ( 36 ) recommend treating these patients on a conservative basis, administering oral antibiotics such as amoxicillin – clavulanic acid 1000/62.5 mg two tablets/day/30 days, or metronidazole 250 mg two tablets/8 hours/10-20 days, and 0.12% chlorhexidine rinses 3-4 times a day. The fistulas in turn can be treated with an intravenous perfusion of ciprofloxacin 2 mg/ml. In a case series published by Marx et al. ( 37 ), 90% of the patients in stages 1 and 2 were stabilized with conservative treatment in the form of oral rinses and systemic antibiotics. Another study ( 25 ) found 3-10% of the patients to fail to respond to conservative treatment or suffer pathological fractures – surgery being needed, with resection of the necrotic bone. The importance of aggressive treatment has been underscored in a study ( 38 ) in which conservative management was not effective. A surgical technique has been described, based on fluorescence guided bone resection of 20 ONJ zones in 15 patients – the success rate being 85% after four weeks of follow-up ( 12 ). The treatment response has been reported to be variable, with a poorer response in patients with maxillary sinusitis associated to ONJ ( 15 ). The treatment guidelines proposed by Bagán et al. ( 32 ) are described in Table 2 .

Prevention

It has long been reported that the determination of CTX (C-terminal telopeptide of type 1 collagen) in the serum of patients treated with BP could be of use in predicting ONJ in patients subjected to oral surgery. Patients with CTX ≥150 pg/ml can undergo any type of surgery with only minimum risks and without the need to suspend the medication; however, in the presence of CTX < 150 pg/ml the risks increase ( 22 ). In contrast, other authors ( 39 , 40 ) have not found CTX to offer any true predictive capacity. As a result, its use must be viewed with caution, and the CTX values cannot be used as a definitive indicator of the risk of suffering BP-induced ONJ. Serum osteocalcin is another marker that could be of use in predicting the risk of ONJ. In this sense, concentrations below the normal limits could indicate problems with the bone formation process, and may be regarded as a risk factor ( 40 ). Periapical X-rays can also be important, revealing sclerotic areas and loss of the inferior alveolar nerve contour caused by progressive sclerosis ( 29 ).

It has been shown that the adoption of preventive measures before and during intravenous BP therapy in cancer patients with bone metastases and in individuals with multiple myeloma is accompanied by a 75% reduction in the incidence of ONJ. Whenever possible, such preventive measures should include adequate oral hygiene before administering BP treatment, together with the extraction of teeth showing a poor prognosis, caries control, and monitorization of the correct fitting of removable dentures ( 2 ). Table 3 summarizes these recommendations, which moreover can be extrapolated to patients treated with bisphosphonates via the oral route ( 8 ).

All patients treated with bisphosphonates are at risk of developing osteonecrosis as a result of such medication. This potential complication therefore should be explained to the patient by both the prescribing physician and the dental surgeon in charge of oral treatment, with the obtainment of informed consent in all cases.

1 Marx RE Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 2003 61 1115 7 12966493 10.1016/s0278-2391(03)00720-1

2 Ruggiero SL Dodson TB Assael LA Landesberg R Marx RE Mehrotra B American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update J Oral Maxillofac Surg 2009 67 2 12 19371809 10.1016/j.joms.2009.01.009

3 Bittner T T Lorbeer N Reuther T Böhm H Kübler AC Müller-Richter UD Hemimandibulectomy after bisphosphonate treatment for complex regional pain syndrome: A case report and review on the prevention and treatment of bisphosphonate-related osteonecrosis of the jaw Oral Surg Oral Med Oral Pathol Oral Radiol Endod Forthcoming 2011 10.1016/j.tripleo.2011.01.017 22677690

4 Borromeo GL Tsao CE Darby IB Ebeling PR A review of the clinical implications of bisphosphonates in dentistry Aust Dent J 2011 56 2 9 21332734 10.1111/j.1834-7819.2010.01283.x

5 Gupta S Jain P Kumar P Parikh PM Zoledronic acid induced osteonecrosis of tibia and femur Indian J Cancer 2009 46 249 250 19574685 10.4103/0019-509X.52967

6 Landesberg R Woo V Cremers S Cozin M Marolt D Vunjak-Novakovic G Potential pathophysiological mechanisms in osteonecrosis of the jaw Ann N Y Acad Sci 2011 1218 62 79 21291478 10.1111/j.1749-6632.2010.05835.x PMC4477826

7 Hoefert S Eufinger H Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw J Oral Maxillofac Surg 2011 69 362 80 21122968 10.1016/j.joms.2010.06.200

8 Bagán JV Diz-Dios P Gallego L Infante-Cossío P Jiménez Y Junquera LM Recomendaciones para la prevención de la osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos intravenosos Med Oral Patol Oral Cir Bucal 2008 13 161 7

9 Manfredi M Merigo E Guidotti R Meleti M Vescovi P Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis Int J Oral Maxillofac Surg 2011 40 277 84 21163625 10.1016/j.ijom.2010.11.002

10 Yoneda T Hagino H Sugimoto T Ohta H Takahashi S Soen S Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons J Bone Miner Metab 2010 28 365 83 20333419 10.1007/s00774-010-0162-7

11 Narongroeknawin P Danila MI Humphreys LG Barasch A Curtis JR Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report Spec Care Dentist 2010 30 77 82 20415805 10.1111/j.1754-4505.2009.00128.x PMC4097110

12 Pautke C Bauer F Otto S Tischer T Steiner T Weitz J Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study J Oral Maxillofac Surg 2011 69 84 91 20971542 10.1016/j.joms.2010.07.014

13 Ferlito S Puzzo S Liardo C Preventive protocol for tooth extractions in patients treated with zoledronate: a case series J Oral Maxillofac Surg 2011 69 e1 4 21316136 10.1016/j.joms.2010.10.055

14 Wutzl A Pohl S Sulzbacher I Seemann R Lauer G Ewers R Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws Head Neck 2012 34 194 200 21400630 10.1002/hed.21708

15 Maurer P Sandulescu T Kriwalsky MS Rashad A Hollstein S Stricker I Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris Int J Oral Maxillofac Surg 2011 40 285 91 21163624 10.1016/j.ijom.2010.11.006

16 Scoletta M Arduino PG Pol R Arata V Silvestri S Chiecchio A Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: a cautionary report J Oral Maxillofac Surg 2011 69 456 62 21129835 10.1016/j.joms.2010.07.026

17 Bagan J Scully C Sabater V Jimenez Y Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update Oral Oncol 2009 45 551 4 19251474 10.1016/j.oraloncology.2009.01.002

18 Reid IR Cundy T Osteonecrosis of the jaw Skeletal Radiol 2009 38 5 9 18649076 10.1007/s00256-008-0549-x

19 Kim RH Lee RS Williams D Bae S Woo J Lieberman M Bisphosphonates induce senescence in normal human oral keratinocytes J Dent Res 2011 90 810 6 21427353 10.1177/0022034511402995 PMC3144120

20 Aghaloo TL Felsenfeld AL Tetradis S Osteonecrosis of the jaw in a patient on denosumab J Oral Maxillofac Surg 2010 68 959 63 20149510 10.1016/j.joms.2009.10.010 PMC2880179

21 Feller L Wood NH Raubenheimer EJ Meyerov R Lemmer J Alveolar bone necrosis and spontaneous tooth exfoliation in an HIVseropositive subject with herpes zoster SADJ 2008 63 106 10 18561810

22 Marx RE Cillo JE Ulloa JJ Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 2007 65 2397 410 18022461 10.1016/j.joms.2007.08.003

23 Grant BT Amenedo C Freeman K Kraut RA Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases J Oral Maxillofac Surg 2008 66 223 30 18201600 10.1016/j.joms.2007.09.019

24 Fugazzotto PA Lightfoot WS Jaffin R Kumar A Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early followup, and the incidence of complications in two private practices J Periodontol 2007 78 1664 9 17760533 10.1902/jop.2007.060514

25 Shirota T Nakamura A Matsui Y Hatori M Nakamura M Shintani S Bisphosphonate-related osteonecrosis of the jaw around dental implants in the maxilla: report of a case Clin Oral Implants Res 2009 20 1402 8 19793318 10.1111/j.1600-0501.2009.01801.x

26 Bagan JV Jimenez Y Murillo J Hernandez S Poveda R Sanchis JM Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases Oral Oncol 2006 42 327 9 16275156 10.1016/j.oraloncology.2005.08.001

27 Ripamonti CI Cislaghi E Mariani L Maniezzo M Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study Oral Oncol 2011 47 185 90 21310650 10.1016/j.oraloncology.2011.01.002

28 Bagan JV Murillo J Jimenez Y Poveda R Milian MA Sanchis JM Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases J Oral Pathol Med 2005 34 120 3 15641993 10.1111/j.1600-0714.2004.00269.x

29 Morag Y Morag-Hezroni M Jamadar DA Ward BB Jacobson JA Zwetchkenbaum SR Bisphosphonate-related osteonecrosis of the jaw: a pictorial review Radiographics 2009 29 1971 84 19926757 10.1148/rg.297095050

30 Ruggiero SL Fantasia J Carlson E Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006 102 433 41 16997108 10.1016/j.tripleo.2006.06.004

31 Ruggiero SL Bisphosphonate-related osteonecrosis of the jaw: an overview Ann N Y Acad Sci 2011 1218 38 46 20946580 10.1111/j.1749-6632.2010.05768.x

32 Bagan JV Jimenez Y Diaz JM Murillo J Sanchis JM Poveda R Osteonecrosis of the jaws in intravenous bisphosphonate use: Proposal for a modification of the clinical classification Oral Oncol 2009 45 645 6 18715813 10.1016/j.oraloncology.2008.05.011

33 Woo SB Mawardi H Treister N Comments on “Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification” Oral Oncol 2009 45 740 19038574 10.1016/j.oraloncology.2008.10.001

34 Bagán J Blade J Cozar JM Constela M García Sanz R Gómez Veiga F Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates Med Oral Patol Oral Cir Bucal 2007 12 E336 40 17664922

35 Marcuzzi A Zanin V Crovella S Pontillo A Comments on ‘’Geranylgeraniol- A new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw” by Ziebart T et al. (2011) Oral Oncol 2011 47 436 7 21411362 10.1016/j.oraloncology.2011.02.017

36 Bocanegra-Pérez S Vicente-Barrero M Sosa-Hernández M Knezevic M Castellano-Navarro JM Rodríguez-Millares J Bisphosphonateassociated osteonecrosis of the jaw. A proposal for conservative treatment Med Oral Patol Oral Cir Bucal 2008 13 E770 3 19047964

37 Marx RE Sawatari Y Fortin M Broumand V Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 2005 63 1567 75 16243172 10.1016/j.joms.2005.07.010

38 Tirelli G Biasotto M Chiandussi S Dore F De Nardi E Di Lenarda R Bisphosphonate-associated osteonecrosis of the jaws: the limits of a con-servative approach Head Neck 2009 31 1249 54 19260132 10.1002/hed.21019

39 Bagan JV Jiménez Y Gómez D Sirera R Poveda R Scully C Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates Oral Oncol 2008 44 1088 9 18396443 10.1016/j.oraloncology.2008.01.012

40 Kwon YD Ohe JY Kim DY Chung DJ Park YD Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res 2011 22 100 5 20946206 10.1111/j.1600-0501.2010.01965.x